• Edwards Lifesciences CVP, TAVR Daniel J. Lippis sold 619 common shares on Oct. 8, 2026 at USD 85.65.
• The sale followed the exercise of 619 employee stock options at USD 72.68 on the same day.
• Directly held common shares stood at 40,033 after the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edwards Lifesciences Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001225208-26-008338), on October 08, 2026, and is solely responsible for the information contained therein.